Your current location:Home > News > Industry News

Targeting the Korean biopharmaceutical market


Time:2024-11-11 10:18:38  Source:  Author:

 

The South Korean biopharmaceutical market has shown strong development momentum. Data shows that in 2022, the size of the South Korean pharmaceutical market exceeded 25 trillion Korean won (approximately 128.58 billion yuan), setting a new historical high. It is expected that from 2023 to 2027, due to the expiration of multiple major original brands, the generic drug market will usher in further growth opportunities. In addition, the Korean medical beauty industry holds an important position globally, and with the continuous advancement of technology and increased international exchanges, the future market prospects are also very broad.

 
 
 
The strong development momentum of the pharmaceutical industry in the country has also brought opportunities to the upstream pharmaceutical equipment industry. Against this backdrop, some strong local pharmaceutical equipment companies are expanding their targets to the South Korean biopharmaceutical market.
 
 
 
It is reported that Chutian Technology, as a leading enterprise in China's pharmaceutical equipment field, has become a model for cooperation with South Korea in the field of medicine and health for more than a decade due to its advanced level and rich pharmaceutical production technology equipment and solutions.
 
 
 
As early as 2008, Chutian Technology entered the Korean market and formed strategic partnerships with numerous Korean pharmaceutical and beauty companies. In 2022, it established a branch in Korea and launched the Korean Sales and Service Center (SSC) to further enhance its localized service level.
 
 
 
In 2023, which marks the 15th anniversary of Chutian Technology's entry into the Korean market, Chutian Technology held a commemorative and customer appreciation event in Korea. Representatives from nearly a hundred Korean client companies participated in the event, and the company stated that it will increase its resource investment in the Korean market, especially accelerate the process of localization construction, be closer to users, provide more professional products, more efficient delivery, and higher quality services, and create greater value for users.
 
 
 
Entering 2024, Chutian Technology has provided more technical equipment and services to the Korean market, especially represented by the whole plant solution created for a medical beauty enterprise. From overall design, equipment design and manufacturing to factory planning, we provide services to users throughout the entire process. Our equipment includes penicillin bottle linkage lines, pre filling systems, blowing and filling systems, isolators, and freeze-drying machines, and comprehensively solves compatibility issues with other auxiliary equipment. Our project delivery speed and quality have been highly praised by users.
 
 
 
During the recent visit of the South Korean media delegation, Chutian Technology further emphasized that it will increase its market and service network construction in South Korea, provide higher-level and more efficient products and services to the South Korean market through specific measures such as optimizing delivery processes, and promote the development of pharmaceutical and health cooperation.
 
 
 
At present, the internationalization pace of Chutian Technology is accelerating. In the first half of this year, Chutian Technology contributed over 334 million yuan in overseas revenue to the Asian region, a year-on-year increase of 65.68%.
 
 
 
The company has stated that it will further strengthen its international market expansion in the future. Based on the promotion of internationalization strategy in recent years, we have increased our expansion into key markets such as Europe and the Americas, expanded the proportion of international markets in the company's business, and improved the overall gross profit margin of the company; At the same time, we will increase the maintenance of the domestic market fundamentals. On the basis of maintaining order volume, order gross profit margin, etc., maintain the company's important position in the domestic market and enhance the industry concentration of the domestic market. At the same time, we will strengthen the sales of accessories and services, achieve differentiated product competition, and improve the overall gross profit margin in China.

Copyright © 2017-2020 SHANGHAI YINGRUI BIOPHARMA CO.,LTD 沪ICP备11038445号-1
TEL:+86-21-33585366(DDT)、34666753 FAX:+86-21-34979012
E-mail:info@shyrchem.com ADD:1885 Metropolitan Road, Minhang District, Shanghai Code:201108